Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
HemoGenyx Pharmaceuticals Plc (GB:HEMO)
LSE:HEMO
Holding GB:HEMO?
Track your performance easily
HEMO Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1.16p - 7.13p
Previous Close1.46p
Volume7.81M
Average Volume (3M)4.45M
Market Cap
£19.59M
Enterprise Value20.45M
Total Cash (Recent Filing)£2.53M
Total Debt (Recent Filing)£3.42M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Sep 26, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,341,815,988
10 Day Avg. Volume7,301,896
30 Day Avg. Volume4,453,647
Standard Deviation0.92
R-Squared0.02
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
HemoGenyx Pharmaceuticals Plc News
PremiumCompany Announcements
HemoGenyx Readies for AML Trial with New Assay
PremiumCompany Announcements
HemoGenyx Advances Cancer Treatment with CDX Antibody
PremiumCompany Announcements
HemoGenyx Showcases CBR Immunotherapy at Conference
PremiumCompany Announcements
HemoGenyx to Showcase Cancer-Fighting Platform
PremiumCompany Announcements
HemoGenyx Shareholders Approve AGM Resolutions
PremiumCompany Announcements
HemoGenyx Advances in Cancer and Viral Disease Treatments
PremiumCompany Announcements
HemoGenyx Pharmaceuticals Schedules AGM, Posts Reports
PremiumCompany Announcements
Hemogenyx Advances Clinical Trials and Secures FundingOptions Prices
Currently, No data available
---
Ownership Overview
9.88%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
90.12% Public Companies and
Individual Investors
HEMO FAQ
What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest share price was 1.16p and its highest was 7.13p in the past 12 months.
What is HemoGenyx Pharmaceuticals Plc’s market cap?
Currently, no data Available
When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Sep 26, 2024 which is in 6 days.
How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
HemoGenyx Pharmaceuticals Plc released its earnings results on Apr 25, 2024. The company reported -0.002p earnings per share for the quarter, missing the consensus estimate of N/A by -0.002p.
Is HemoGenyx Pharmaceuticals Plc overvalued?
According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued.
Does HemoGenyx Pharmaceuticals Plc pay dividends?
HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
HemoGenyx Pharmaceuticals Plc has 1,341,816,000 shares outstanding.
What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
HemoGenyx Pharmaceuticals Plc reported an EPS of -0.002p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.863%.
Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in GB:HEMO
---
HemoGenyx Pharmaceuticals Plc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.74%
12-Months-Change
Fundamentals
Return on Equity
-219.58%
Trailing 12-Months
Asset Growth
-13.91%
Trailing 12-Months
Company Description
HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals PLC and its subsidiary is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy.
---
Technical Analysis
---